PREVENTING NSAID INDUCED GI COMPLICATIONS: AN ECONOMIC EVALUATION OF ALTERNATIVE STRATEGIES IN CANADA. February 13, 2007
|
|
- Clement Harvey
- 6 years ago
- Views:
Transcription
1 PREVENTING NSAID INDUCED GI COMPLICATIONS: AN ECONOMIC EVALUATION OF ALTERNATIVE STRATEGIES IN CANADA February 13, 2007 Canadian Agency for Drugs and Technologies in Health (CADTH)
2 TABLE OF CONTENTS 1.0 INTRODUCTION OBJECTIVE METHODS ANALYTICAL APPROACH POPULATION TREATMENT COMPARATORS AUDIENCE AND PERSPECTIVE CLINICAL EVENTS COSTING DATA RESOURCE USE UTILITIES SENSITIVITY ANALYSIS RESULTS BASE CASE ANALYSIS PROBABILISTIC SENSITIVITY ANALYSIS LIMITATIONS DISCUSSION CONCLUSIONS ACKNOWLEDGEMENTS REFERENCES...22 FIGURES Figure 1: Decision analytic model used in the economic analysis. [+] represents a sub-tree not shown in figure that is identical to sub-tree in NSAID alone...6 Figure 2: Cost-effectiveness plane of gastroprotective strategies in Canada...15 Figure 3: Cost-effectiveness scatter plot of COMPUS model from Monte Carlo simulation: Costs and QALYs...16 Figure 4: Incremental cost-effectiveness scatter plot of PPIs relative to no prophylaxis in Monte Carlo simulation: Costs and QALYs at WTP = $50,000. Vertical dashed line represents incremental effectiveness of zero, diagonal dashed line indicates WTP threshold of $50,000 per QALY gained...17 Figure 5: Cost-effectiveness acceptability curve of COMPUS Economic model...18 TABLES Table 1: Adverse event rates for alternative gastroprotective strategies in patients taking NSAIDs for more than 3 weeks Table 2: Mean estimates (95% CIs) for treatment pathway probabilities for patients in nonselective NSAID alone treatment arm...8 Table 3: Mean estimates (95% CIs) for treatment pathway probabilities obtained from MUCOSA trial 4,16 for patients in non-selective NSAID + GPA and selective COX-2 treatment arms...8 Table 4: Cost data used in economic analysis...9 Table 5: Resource use associated with each treatment pathway adapted from Elliott et al., (2006) Table 6: Utility and Duration of GI Events, adopted from Elliott et al., (2006) Preventing NSAID induced GI complications: an economic evaluation of alternative strategies in Canada 2
3 Table 7: Expected costs, QALYs, costs per QALY and incremental costs per QALY gained for alternative gastrointestinal prophylaxis therapies in Canada...14 Table 8: Expected values and standard deviations for costs, QALYs, cost per QALY in economic analysis from Monte Carlo Simulation...15 Table 9: Proportion of samples from each component region in ICE scatter plot...17 Preventing NSAID induced GI complications: an economic evaluation of alternative strategies in Canada 3
4 1.0 INTRODUCTION Non-steroidal anti-inflammatory drugs (NSAID) are widely prescribed to prevent pain and inflammation in patients with osteoarthritis (OA) and rheumatoid arthritis (RA). In 2004, approximately 13 million NSAID prescriptions were dispensed in Canada. 1 It is estimated that per capita expenditure on oral anti-arthritic agents increased from $9 in 1998 to $21 in Although NSAIDs are effective anti-inflammatory and analgesic agents, overwhelming evidence links NSAID use to a variety of gastrointestinal (GI) complications including gastric and duodenal ulcers, dyspepsia, GI bleeding, perforations, gastric outlet obstructions, and death. 2-5 The risk of a NSAID-induced GI event increases with the presence of risk factors including advanced age, previous GI ulcer or bleed, and concomitant use of corticosteroids, anticoagulants or anti-platelet agents. 2-5 NSAID induced complications are estimated to cause 3,897 hospitalizations and 365 deaths each year in Canada. 6 It is estimated that for each dollar spent on NSAIDs in Canada, an additional $0.66 was spent on the treatment of side effects. 7 Therefore, optimal prescribing of gastrointestinal prophylaxis agents in patients receiving NSAIDs is paramount. To prevent NSAID-induced GI complications, patients taking NSAIDs are often prescribed a gastrointestinal prophylaxis agent (GPA). The GPAs available in Canada include proton pump inhibitors (PPIs), histamine2-receptor antagonists (H2RAs), and misoprostol. Alternatively, COX-2 selective NSAIDs may be prescribed instead of a non-selective NSAID in combination with a GPA, since these agents have a lower risk of ulcer and ulcer complications than non-selective NSAIDs alone. Together, the GPAs and COX-2 selective NSAIDs represent alternative gastroprotective strategies for the prevention of ulcers in patients requiring NSAID therapy. According to the Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) Evidence for PPI use in gastroesophageal reflux disease, dyspepsia and peptic ulcer disease, Scientific Report, 8 standard dose PPIs in combination with non-selective NSAIDs are more efficacious than standard dose H2RAs, and equally efficacious as misoprostol or COX-2 selective NSAIDs for ulcer prevention. However, there have been no recent evaluations that have adequately addressed the economic question of the use of gastroprotective strategies within a Canadian context. Therefore, a need existed to conduct an economic evaluation in order to provide information on the relative cost-effectiveness of the available strategies. Preventing NSAID induced GI complications: an economic evaluation of alternative strategies in Canada 4
5 2.0 OBJECTIVE The objective of this study was to assess the relative cost-utility of PPIs in preventing NSAID-associated GI complications relative to alternative strategies in patients with chronic musculoskeletal conditions (primarily RA and OA) who require NSAID therapy for more than 3 weeks. 3.0 METHODS Given that we did not identify any recent economic evaluations that adequately addressed our study question within a Canadian context; we conducted our own economic evaluation, adapted from previous economic analyses. 9, ANALYTICAL APPROACH To evaluate the cost-utility of gastrointestinal prophylaxis in preventing NSAID associated GI complications, a decision analytical model was developed (Figure 1). The model was adapted from recently published economic analyses that were conducted in the United Kingdom. 9,10 A static, decision tree model was selected because data was not available to populate a more complex model and we did not want to weaken the model structure with excessive assumptions. Model structure was validated by gastroenterologists from the COMPUS PPI Expert Review Panel. The outputs for the model were cost, Quality adjusted life year (QALYs) gained, cost per QALY gained, and incremental cost per QALY gained. A probabilistic sensitivity analysis was conducted to incorporate uncertainty, along with cost-effectiveness acceptability curves. All analyses were performed using TreeAge Pro Preventing NSAID induced GI complications: an economic evaluation of alternative strategies in Canada 5
6 Figure 1: Decision analytic model used in the economic analysis. [+] represents a subtree not shown in figure that is identical to sub-tree in NSAID alone POPULATION The cost-utility of each strategy in preventing GI complications was evaluated in a simulated cohort of patients (age 18 years) beginning a 6-month course of NSAID therapy. The baseline population of interest consisted of patients enrolled in clinical trials (age 18 years), examined in a recent systematic review and meta-analysis. 9,11 Patients entered the model and were treated with one of five alternative gastroprotective strategies (listed below) TREATMENT COMPARATORS We compared the cost-utility of PPIs in preventing GI complications relative to alternative GPAs for adult patients in Canada who were taking NSAIDs. Drug therapies and dosages used in the model were: NSAID: diclofenac 50 mg bid H2RA: ranitidine 300 mg bid* PPI: omeprazole 20 mg od* Misoprostol 200 µg qid* Cox2: celecoxib 200mg bid *Doses selected are efficacious in preventing NSAID induced gastric and duodenal endoscopic ulcers. 12 Preventing NSAID induced GI complications: an economic evaluation of alternative strategies in Canada 6
7 As shown in Figure 1, patients entering the model were treated with one of the following: Non-selective NSAID alone Non-selective NSAID+ H 2 -Receptor Antagonist (H2RA) Non-selective NSAID+ Proton Pump Inhibitor (PPI) Non-selective NSAID+ misoprostol Selective Cox-2 inhibitor In the case of persistent GI discomfort (dyspepsia), patients were switched to alternative gastroprotective therapies. Switching patterns, which were based on switching patterns in previously published economic models, 9,10 were: Non-selective NSAID alone to Non-selective NSAID+PPI Non-selective NSAID+ H2RA to Non-selective NSAID+PPI Non-selective NSAID+PPI to Selective Cox-2 inhibitors Non-selective NSAID+ misoprostol to Non-selective NSAID+PPI Selective Cox-2 inhibitors to Non-selective NSAID+PPI 3.04 AUDIENCE AND PERSPECTIVE The target audience for this economic evaluation included provincial public drug benefit plans and provincial health ministries. The economic evaluation takes the perspective of a third party provincial payer, as recommended in Canadian Agency for Drugs and technologies in Health (CADTH) guidelines CLINICAL EVENTS Rates of adverse events for each of the five strategies were obtained from a previously published systematic review and meta-analysis. 9 Adverse events included in the model were defined as follows: Dyspepsia- moderate to severe GI discomfort Serious GI complication- any of the following: GI hemorrhage, perforation, or gastric outlet obstruction. Symptomatic Uncomplicated Ulcer- a symptomatic, uncomplicated gastric or duodenal ulcer confirmed by endoscopy. GI-related death- mortality associated with serious GI ulcer complication requiring inpatient management. The mortality rate was assumed to be 5.5%. 14 Rates for GI discomfort, symptomatic and endoscopic ulcer, and serious GI complications are presented in Table 1. Table 1: Adverse event rates for alternative gastroprotective strategies in patients taking NSAIDs for more than 3 weeks. 9 GI Symptomatic/ Serious GI complications Strategy discomfort endoscopic ulcer NSAID NSAID+H2RA NSAID+PPI Preventing NSAID induced GI complications: an economic evaluation of alternative strategies in Canada 7
8 NSAID+Misoprostol Celecoxib Notes: 1. The probability of no GI adverse event = 1 - (p(gi discomfort) + p(symptomatic/endoscopic ulcer) + p(serious GI complication)) 2. The estimates for the baseline risk of each event were calculated from the MA assuming that the control arm represented using an NSAID alone. Probability = (number of events in control group NSAID plus H2RA studies + number of events in control group NSAID plus PPI studies + number of events in control group NSAID plus misoprostol studies + number of events in control group Cox2 studies + number of events in control group Cox2 preferential studies) / (sample size in control group NSAID plus H2RA studies + sample size in control group NSAID plus PPI studies + sample size in control group NSAID plus misoprostol studies + sample size in control group Cox2 studies + sample size in control group Cox2 preferential studies) 3. The probability of symptomatic/endoscopic ulcer = 0.15*p(endoscopic ulcer) (Based on MUCOSA 4 study estimate of 85% of endoscopic ulcer remained silent) 4. The probability of each event = baseline risk of each event from NSAID arm * RR ratio from MA Treatment pathway probabilities were derived from the Misoprostol Ulcer Complications Outcomes Safety Assessment (MUCOSA) trial 4 and The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE) study. 14 All treatment pathway probabilities in the analysis were assigned a beta distribution. 15 Table 2 and Table 3 present treatment pathway probabilities obtained from the MUCOSA trial 4,16 for patients in nonselective NSAID alone treatment arm, and for patients in non-selective NSAID + GPA treatment arms, respectively. Table 2: Mean estimates (95% CIs) for treatment pathway probabilities for patients in non-selective NSAID alone treatment arm Treatment Pathway Probability (95% CI) Investigation after GI discomfort** ( ) Inpatient management of GI discomfort** 0.24 ( ) Outpatient endoscopy of GI discomfort** 0.35 ( ) Endoscopy, given ulcer** 0.27 ( ) Inpatient management of GI complication** 0.67 ( ) Death, given inpatient management of GI complication* * The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy RUGBE study 14 ** Misoprostol Ulcer Complications Outcomes Safety Assessment (MUCOSA) trial 4 Table 3: Mean estimates (95% CIs) for treatment pathway probabilities obtained from MUCOSA trial 4,16 for patients in non-selective NSAID + GPA and selective COX-2 treatment arms. Treatment Pathway Probability (95% CI) Investigation after GI discomfort** ( ) Inpatient management of GI discomfort** 0.39 ( ) Outpatient endoscopy of GI discomfort** 0.15 ( ) Endoscopy, given ulcer** 0.27 ( ) Inpatient management of GI complication** 0.56 ( ) Death, given inpatient management of GI complication* * The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy RUGBE study 14 ** Misoprostol Ulcer Complications Outcomes Safety Assessment (MUCOSA) trial 4 Preventing NSAID induced GI complications: an economic evaluation of alternative strategies in Canada 8
9 Patients on misoprostol were assumed to have an intolerance rate (requiring switching to another gastroprotective strategy) of 5.11%. The probability of intolerance to misoprostol was calculated as the difference between the drop out rate due to GI symptoms in the misoprostol arm and the placebo arm of the systematic review and meta-analysis. 9 All other strategies were assigned an equivalent intolerance rate to placebo COSTING DATA Costs were from a third party provincial payer perspective. Costs were calculated and presented in Canadian dollars. Physician Fees and Procedures Costs for physician fees and procedures were obtained from the Ontario Ministry of Health and Long Term Care Schedule of benefits, October 1, Costs of physician fees and procedures are provided in Table 4. Drugs Drug costs were base unit costs from the Ontario Drug Benefit Formulary September 2005, plus an allowable markup of 10% and a pharmacy fee of $7.00. The lowest generic cost was used for each alternative, where possible. Unit drug costs per day are presented in Table 4. In-patient and Out-patient Management In-patient and out-patient costs were obtained from the Health Costing in Alberta 2006 Annual Report. 17 Costing data for the Alberta Case Costing Report is generated from the cost of cases in 2 health authorities and 12 sites in Alberta from April 1, 2004 to March 31, Those data do not include payments made to physicians and other allied health professions. Associated costs per case for in-patient and out-patient management of GI complications are presented in Table 4, along with Case Mix Groupings (CMG) and Ambulatory Case Classification System (ACCS) codes. In-patient and out-patient aggregated costs were assigned a gamma distribution in the analysis. The gamma distribution is commonly assigned to costing estimates in economic evaluations because it is constrained to be positive and continuous. 15 Table 4: Cost data used in economic analysis Parameter Cost Estimate ($CAD) Drug Treatments (per day) Diclofenac 50mg bid 1.10 Omeprazole 20 mg od 1.61 Misoprostol 200 μg qid 1.49 Ranitidine, 300 mg bid 1.96 Celecoxib 200mg bid 2.97 Acetaminophen (1gm qid) * 0.37 Physician Fees and Procedures ** Preventing NSAID induced GI complications: an economic evaluation of alternative strategies in Canada 9
10 GP Visit Gastroenterologist, visit with consultation Subsequent Inpatient visit with Gastroenterologist Endoscopic treatment fee In-patient and out-patient costs Diagnostic Endoscopy Therapeutic Endoscopy 453 (s.d = 252) Out-patient, gastroenterology Management, general gastrointestinal, Age 18+ ζ 134 (s.d = 134) Out-patient Management GI Bleed/Perforation/Obstruction ρ 231 (s.d = 220) GI Hemorrhage- Inpatient medical management φ 4006 (s.d = 3600) In-patient day for stomach problem ώ Drug Costs based on Ontario Drug Plan 2005, plus an allowable mark-up 10% and a pharmacy fee for 28 days supply * Maetzel et al (2003) 18 Ontario Drug Benefit Plan (1999) Crott et al.,(2002) 19 ** Ontario Ministry of Health and Long Term Care, January Health Costing in Alberta 2006 Annual Report, Ambulatory Care Costs, ACCS Code= ζ Health Costing in Alberta 2006 Annual Report, Ambulatory Care Costs, Weighted average of ACCS Code= 409, 410, and ρ Health Costing in Alberta 2006 Annual Report, Ambulatory Care Costs, ACCS Code= φ Health Costing in Alberta 2006 Annual Report, In-patient Costing Data, CMG Group= ώ Health Costing in Alberta 2006 Annual Report, In-patient Costing Data, Weighted Average of GI CMG Groups RESOURCE USE Associated resource use for each treatment pathway was adapted from a recent economic evaluation conducted in the United Kingdom 10 to reflect the Canadian setting. Table 5 presents resource use with each treatment pathway. Preventing NSAID induced GI complications: an economic evaluation of alternative strategies in Canada 10
11 Table 5: Resource use associated with each treatment pathway adapted from Elliott et al., (2006) 10 Treatment Pathway No GI adverse Event GI Discomfort: therapy switch, with no investigation GI Discomfort: investigated, inpatient management GI Discomfort; outpatient management with endoscopy GI Discomfort; outpatient managementno endoscopy Symptomatic, uncomplicated ulcer: endoscopy Symptomatic, uncomplicated ulcer: no endoscopy Serious GI complication: outpatient management Serious GI complication: inpatient medical management Cost Estimation 6 months of first drug treatment 1 month of first drug treatment, 1 GP visit, 5 months' switched drug treatment 1 1 month of first drug treatment, 2 inpatient days for stomach problem, 2 visits with GP, PPI for 28 days, diagnostic endoscopy, 1 outpatient visit, outpatient general gastrointestinal management, age 18, 5 months' switched drug treatment 1 month of first drug treatment, 2 visits with GP, PPI for 28 days, 1 outpatient visit, diagnostic endoscopy, therapeutic endoscopy 3, outpatient general gastrointestinal management, age 18, 5 months' switched drug treatment 1 month of first drug treatment, 2 visits with GP, PPI for 28 days, 1 outpatient visit, outpatient general gastrointestinal management, age 18, 5 months' switched drug treatment 3 months of first drug treatment, diagnostic endoscopy, therapeutic endoscopy 3, 2 visits with GP, PPI for 28 days, 2 outpatient visits, outpatient general gastrointestinal management-age 18, 3 months' paracetamol treatment 3 months of first drug treatment, 2 visits with GP, PPI for 28 days, 2 outpatient visits, 2 outpatient Gastrointestinal Management Age 18, 3 months' paracetamol treatment 3 months of first drug treatment, 42 days' oral PPI, 2 visits with GP, 2 outpatient visits, diagnostic endoscopy, therapeutic endoscopy 3, outpatient management GI Bleed/Perforation/Obstruction, 3 months' paracetamol treatment 3 months of first drug treatment, 42 days' oral PPI, 2 visits with GP, 2 outpatient visits, GI bleed: inpatient managemen of serious GI event costs, 3 months' paracetamol treatment 1 Patients were switched to alternative therapy as outlined in Section The associated cost of an outpatient visit was assumed to be equivalent to the weighted cost of outpatient management 4, gastroenterology age 18 from Alberta Case Costing Report and outpatient physician fee 17 3 The associated cost of a therapeutic endoscopy is assumed to be equivalent to the cost of an endoscopy from the Alberta 2006 Case Costing Ambulatory Care 17 statistics and endoscopy fee from the Ontario Fee Schedule 4 These costs include all indirect and direct costs (salaries, drugs, medical, and surgical supplies) and other expenses in patient care centers. They exclude payments made to physicians and other allied health professionals The indirect and direct cost of a patient that survives and dies from a serious GI complication is assumed to be equivalent Preventing NSAID induced GI complications: an economic evaluation of alternative strategies in Canada 11
12 3.08 UTILITIES Utility values were adopted from a recent economic model. 10 Table 6 presents the utility of 1) each GI adverse event health state, 2) duration of health state in days, and 3) QALYs lost over 6 months, for the 10 health states in the model. Given the lack of data surrounding variance of GI utility estimates, QALYs lost over 6 months were assigned a triangular distribution. In some instances, the range around the mean was too wide, so a βeta distribution was assigned. QALYs lost over 6 months were subtracted from the average life expectancy of individuals aged 18 taking NSAIDs. The mean age of participants in the 112 RCTs (74,666 patients) was not given. However, a mean age of 58 years was assumed in the model. This age was selected because the majority (101) of RCTs included (112) in the meta-analysis reported a mean age of < 65 years 10 and the mean age of patients in two recent large (16,135 patients) prospective RCTs 5,21 was approximately 58 years. We obtained an estimated life expectancy at age 58 for the Canadian population from Statistics Canada. 22 Life years were discounted by 5% as recommended by CADTH guidelines SENSITIVITY ANALYSIS A probabilistic sensitivity analysis using Monte Carlo Simulation was utilized to incorporate uncertainty of parameters. Monte Carlo simulation enables simultaneous sensitivity analysis of all uncertain variables 23 by replacing point estimates of probabilities, utilities, and costs with probability distributions. Probability distributions for this model were derived from previous economic analyses. 9 The probabilistic analysis sums the results of 10,000 iterations where each iteration randomly samples parameter values from specified distributions. Cost-effectiveness scatter plots and cost-effectiveness acceptability curves were generated to convey uncertainty of results. The simulation software utilized to conduct the sensitivity analysis was TreeAge Pro Preventing NSAID induced GI complications: an economic evaluation of alternative strategies in Canada 12
13 Table 6: Utility and Duration of GI Events, adopted from Elliott et al., (2006) 10 Treatment pathway Utility Duration QALY lost over 6 months No GI adverse event GI discomfort, switch therapy: moderate dyspepsia before seeking help GI discomfort, in-patient medical management: severe dyspepsia before seeking help in-patient days with endoscopy severe dyspepsia after therapy moderate dyspepsia after therapy GI discomfort, out-patient medical management, endoscopy: severe dyspepsia before seeking help out-patient endoscopy severe dyspepsia after therapy moderate dyspepsia after therapy GI discomfort, out-patient medical management, no endoscopy: severe dyspepsia before seeking help severe dyspepsia after therapy moderate dyspepsia after therapy Symptomatic ulcer, endoscopy: severe dyspepsia before seeking help out-patient endoscopy (2) severe dyspepsia after therapy moderate dyspepsia after therapy Symptomatic ulcer, no endoscopy: severe dyspepsia before seeking help severe dyspepsia after therapy moderate dyspepsia after therapy Serious GI complication, inpatient management, survive: severe dyspepsia before seeking help in-patient treatment of complicated ulcer * severe dyspepsia after therapy moderate dyspepsia after therapy serious GI complication, inpatient management, die Serious GI complication, outpatient management: severe dyspepsia before seeking help out-patient endoscopy (2) severe dyspepsia after therapy moderate dyspepsia after therapy * Average length of stay for in-patient management of serious GI complication (hemorrhage, perforation, gastric outlet obstruction) in Canadian setting (Alberta Case Costing Report). 17 Preventing NSAID induced GI complications: an economic evaluation of alternative strategies in Canada 13
14 4.0 RESULTS 4.01 BASE CASE ANALYSIS The results of the base case analysis are provided in Table 7 and a graphical illustration of the results is provided in Figure 2. In the base-case analysis, selective COX-2 inhibitor therapy is dominated. That is, selective COX-2 inhibitor therapy is more costly and less effective than a number of other alternatives. Of the non-dominated strategies, non-selective NSAID therapy alone (i.e., with no prophylaxis) is the least costly but least effective strategy. NSAID + misoprostol (200µg qid) is removed from the results by extended dominance. Although NSAID + misoprostol (200µg qid) is cheaper than NSAID +PPI, NSAID + PPIs is a better value for money (i.e., this strategy has a lower ICER as compared to no prophylaxis than does misoprostol). NSAID + PPI is $190 more costly per person and yields additional QALYs relative to NSAID alone. NSAID+PPI is estimated to cost $74,383 per QALY more than NSAID alone therapy. Table 7: Expected costs, QALYs, costs per QALY and incremental costs per QALY gained for alternative gastrointestinal prophylaxis therapies in Canada Strategy Cost ($CAD) Incr Cost Effectiveness (QALY) Incr Eff C/E Incr C/E (ICER)* a.) All options ordered by increasing cost NSAID alone N/A N/A N/A NSAID+misoprostol ,688 NSAID+PPI ,470 COX (Dominated) NSAID+H2RA ,410,471 b.) Without dominated options (simple or extended) NSAID alone NSAID+PPI ,383 NSAID+H2RA ,410,471 * Incremental cost per QALY gained The state when an intervention is not preferred because there is an alternative treatment that is cheaper and more effective. 24 Preventing NSAID induced GI complications: an economic evaluation of alternative strategies in Canada 14
15 Figure 2: Cost-effectiveness plane of gastroprotective strategies in Canada 4.02 PROBABILISTIC SENSITIVITY ANALYSIS Table 8 provides estimates of the standard deviation for the average cost, QALYs gained, and cost per QALY gained generated from the Monte Carlo simulation. Figure 3 displays the cost-effectiveness (CE) scatter plot for all iterations in the Monte Carlo simulation. Each point in the CE scatterplot represents the cost and effectiveness (QALYs) for each strategy associated with a particular iteration in the Monte Carlo simulation. The Y-axis is truncated in the CE scatter plot to better illustrate results. Table 8: Expected values and standard deviations for costs, QALYs, cost per QALY in economic analysis from Monte Carlo Simulation Strategy Cost ($CAD) Effectiveness (QALY) C/E ($/QALY) NSAID alone (SD = 19.09) (SD = ) (SD = 1.29) NSAID + misoprostol (SD = 9.50) (SD = ) (SD = 0.64) NSAID + PPI (SD = 16.11) (SD = ) (SD = 1.09) COX-2 Inhibitors (SD = 7.63) (SD = ) (SD = 0.52) NSAID + H2RA (SD = 51.14) (SD = ) (SD = 3.50) Preventing NSAID induced GI complications: an economic evaluation of alternative strategies in Canada 15
16 Figure 3: Cost-effectiveness scatter plot of COMPUS model from Monte Carlo simulation: Costs and QALYs Figure 4 displays the ICE scatter plot from the Monte Carlo simulation for NSAID and PPI versus NSAID alone. Each point represents the incremental cost and effectiveness of PPIs relative to no prophylaxis for a particular iteration. Table 9 provides the text report for the ICE scatter plot. The table illustrates that 25.05% of the PPI samples in the Monte Carlo simulation are cost-effective relative to no prophylaxis at a willingness to pay threshold of $50,000 per QALY gained. Preventing NSAID induced GI complications: an economic evaluation of alternative strategies in Canada 16
17 Figure 4: Incremental cost-effectiveness scatter plot of PPIs relative to no prophylaxis in Monte Carlo simulation: Costs and QALYs at WTP = $50,000. Vertical dashed line represents incremental effectiveness of zero, diagonal dashed line indicates WTP threshold of $50,000 per QALY gained. Table 9: Proportion of samples from each component region in ICE scatter plot Component Quadrant Incr. Eff. Incr. Cost ICER # Points Percent C1 IV IE>0 IC<0 Superior % C2 I IE>0 IC>0 < % C3 III IE<0 IC<0 > % C4 I IE>0 IC>0 > % C5 III IE<0 IC<0 < % C6 II IE<0 IC>0 Inferior % **To identify cost-effective points, a different component labeling system is used. Cost-effective points for NSAID+PPI lie below the WTP line ($50,000 per QALY), in components 1-3. Component 1 (C1) is where NSAID+PPI is dominant ( Superior ) Component 2 (C2) is where NSAID+PPI is more costly, but lies below the WTP Component 3 (C3) is where NSAID+PPI is less costly, but lies below the WTP Component 4 (C4) is where NSAID+PPI is more costly, and lies above the WTP. Component 5 (C5) is where NSAID+PPI is less costly, and lies above the WTP. Component 6 (C6) is where NSAID+PPI is dominated ( Inferior ). Figure 5 illustrates the cost-effectiveness acceptability curve for all strategies in the economic analysis. The proportion of non-selective NSAID+PPI samples that are the most cost-effective at a WTP threshold of $50,000 and $100,000 per QALY gained is 24.9% and 63.0%, respectively. The likelihood that NSAID+H2RA is the most costeffective strategy at a WTP threshold of $50,000 and $100,000 is 0.8% and 33.0%, respectively. Preventing NSAID induced GI complications: an economic evaluation of alternative strategies in Canada 17
18 Figure 5: Cost-effectiveness acceptability curve of COMPUS Economic model 5.0 LIMITATIONS The interpretation of results in this economic evaluation is limited by several key assumptions/limitations: Poor data quality on clinical outcomes in some strategies. The efficacy of PPIs and H2RAs in preventing clinical GI complications was estimated from trials with very low event rates. Input parameters for the model were derived from a meta-analysis of RCTs that varied in study design, population, NSAID prescribed, dose, duration and quality. Indirect comparisons were used to generate event rates rather than direct comparisons. The cost of the H2RA strategy was based on double-dose therapy (ranitidine 300mg bid), and that of misoprostol, on a daily dose of 800 mcg/day. Although higher than routinely used in clinical practice, these doses have been shown to be most efficacious in preventing both gastric and duodenal ulcers. Diclofenac was chosen to represent non-selective NSAIDs; other agents in this class have different costs and propensity to cause gastropathy. Dose response relationships of strategies were not incorporated into analysis. Estimates surrounding the efficacy of strategies were based on pooled results from RCTs employing different dosages. Given the lack of data surrounding utilities of GI states, utility measures had to be obtained from disparate sources that studied different populations and utilized different utility measures. Preventing NSAID induced GI complications: an economic evaluation of alternative strategies in Canada 18
19 Most treatment pathway probabilities were obtained from a single RCT. 4 The study population in this trial may have differed from overall population in meta-analysis from which even rates were derived. Non-adherence resulting from multiple daily dosing was not incorporated into analysis; assumed that patients taking four times daily therapy (i.e. misoprostol) have equivalent adherence to patients taking once daily therapy. Intolerance rate of misoprostol was estimated from pooled estimate of misoprostol RCT studies that varied in dose, duration, design, study population, NSAID prescribed, and methodological quality. Switching patterns for patients experiencing GI discomfort vary across treatment strategies. Data on resource use associated with NSAID-related GI events was of poor quality. The model assumes equivalent resource utilization to recent economic models in the UK, 9,10 adapted to a Canadian context. It was assumed that 15% of endoscopic ulcers become symptomatic uncomplicated ulcers, as estimated in the MUCOSA trial. 4 Model did not incorporate reimbursement schemes of drug therapies into analysis. Drug costs are based on unit costs in the Ontario Drug Benefit Formulary September 2005, plus an allowable markup of 10% and a pharmacy fee of $7.00. Adverse event rates were derived from randomized controlled trials; study populations may differ from real world populations. Lack of data to populate model for population at high-risk for NSAID-induced eulcer complications, a group in which gastroprotection may be most cost-effective. 6.0 DISCUSSION Despite poor data quality surrounding clinical outcomes, this model generated some useful results for decision makers and healthcare managers. Among non-dominated strategies, our analysis found that the use of non-selective NSAID+PPI or NSAID+H2RA therapy may reduce the risk of serious GI complications, albeit at an increased cost to the healthcare system relative to NSAIDs alone. In the base case analysis, compared to NSAID therapy alone, NSAID+PPI therapy was associated with a cost of $74,383 per QALY gained. NSAID+ H2RA therapy was associated with an incremental cost of $1,410,471 per QALY gained relative to NSAID+PPI. However, these results should be interpreted with caution as they are based on parameters associated with high levels of uncertainty. For example, event rates for serious GI complications with PPI or H2RA prophylaxis were derived from trials with exceedingly low event rates. Other caveats as outlined under Limitations also apply. The probabilistic sensitivity analysis and the corresponding cost-effectiveness acceptability curves indicate that the proportion of NSAID+PPI samples that are the most cost-effective is approximately 25% at a WTP threshold of $50,000 per QALY gained. Preventing NSAID induced GI complications: an economic evaluation of alternative strategies in Canada 19
20 The risk of NSAID-induced GI event increases with the presence of risk factors, which in turn, will affect the relative cost-effectiveness of the various strategies modeled. However, we were not able to assess the effect of such risk factors on cost-effectiveness due to the poor quality surrounding clinical outcomes or lack of such data. Future studies examining the effect of risk factors or stratifying patients by risk will provide useful information for decision makers, particularly provincial drug benefit plans. To date, no large, prospective, randomized, controlled clinical outcome studies have been conducted to examine the efficacy of PPIs or H2RAs in preventing NSAID-associated clinical GI complications. Given the widespread use of these therapies, a large prospective RCT and economic evaluation examining clinical outcomes across strategies would yield valuable information to decision makers and healthcare managers. Acknowledging limitations, this model generated some useful results for decision makers. These findings highlight the relative cost-utility of gastrointestinal prophylaxis strategies in preventing NSAID-associated GI complications in the Canadian context. The results can be utilized to aide decision makers, physicians, and other health professionals on how to prescribe gastroprotective agents appropriately and costeffectively. 7.0 CONCLUSIONS The economically preferred gastroprotective strategy for patients receiving NSAIDs is dependent upon decision makers willingness to pay. A strategy of no prophylaxis (i.e., non-selective NSAID alone) is the least costly, but also the least effective, strategy in a cohort of patients (age 18) beginning a 6-month course of NSAID therapy. Non-selective NSAID+PPI or NSAID+H2RA therapies may reduce the risk of serious GI complications, albeit at an increased cost to the healthcare system. Compared to no prophylaxis, PPI therapy is cost-effective as a gastroprotective strategy in NSAID users when a cost exceeding $74,383 per QALY gained is acceptable. With an incremental cost per QALY exceeding $1 million as compared to NSAID+PPI, NSAID + H2RA therapy is not a cost-effective strategy. COX-2 selective NSAIDs and misoprostol are dominated alternatives. When uncertainty is incorporated in the analysis through the use of a Monte Carlo simulation, the strategy with the highest likelihood of being the most cost-effective alternative is non-selective NSAID alone up to a WTP threshold of $62,000 per QALY gained. Beyond this threshold, NSAID+PPI has the highest probability of being the most cost-effective strategy. The probability that non-selective NSAID+PPI is the most costeffective strategy at WTP thresholds of $50,000 and $100,000 per QALY gained is 24.9% and 63.0%, respectively. In contrast, the likelihood that NSAID+H2RA is the most cost-effective strategy at WTP thresholds of $50,000 and $100,000 is 0.8% and 33.0%, respectively. Preventing NSAID induced GI complications: an economic evaluation of alternative strategies in Canada 20
21 8.0 ACKNOWLEDGEMENTS We acknowledge the contributions of COMPUS expert review panel, specifically the gastroenterologists for their expert advice and COMPUS Research Officer Sumeet Singh for his inputs. Preventing NSAID induced GI complications: an economic evaluation of alternative strategies in Canada 21
22 9.0 REFERENCES 1. Ref ID: 3124 Morgan S, McMahon M, Lam J, Mooney D, Raymond C. The Canadian Rx atlas. Vancouver: Centre for Health Services and Policy Research. University of British Columbia; 2005 Dec. Available: (accessed 2006 Sep 6). 2. Ref ID: 3728 Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343(21):1520-8, Ref ID: 2888 Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D, Brett C, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a doubleblind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002;123(4): Ref ID: 3318 Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123(4): Ref ID: 3305 Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284(10): Ref ID: 3736 Tamblyn R, Berkson L, Dauphinee WD, Gayton D, Grad R, Huang A, et al. Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice. Ann Intern Med 1997;127(6): Ref ID: 3737 Rahme E, Joseph L, Kong SX, Watson DJ, LeLorier J. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population. Arthritis Rheum 2000;43(4): Ref ID: 3718 Canadian Agency for Drugs and Technologies in Health. Evidence for PPI use in Preventing NSAID induced GI complications: an economic evaluation of alternative strategies in Canada 22
23 gastroesophageal reflux disease, dyspepsia and peptic ulcer disease [Scientific report]. DRAFT. Ottawa: The Agency; 2006 Dec Ref ID: 3727 Brown TJ, Hooper L, Elliott RA, Payne K, Webb R, Roberts C, et al. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal antiinflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling. Health Technol Assess 2006;10(38):iii-xiii, Ref ID: 3095 Elliott RA, Hooper L, Payne K, Brown TJ, Roberts C, Symmons D. Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population? Rheumatology (Oxford) 2006;45(5): Ref ID: 2484 Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by nonsteroidal anti-inflammatory drugs: systematic review: abridged version. BMJ (Clinical research ed ) 2004;329(7472): Available: (accessed 2007 Feb 14). 12. Ref ID: 2786 Rostom A, Dubé C, Jolicoeur E, Boucher M, Joyce J. Gastro-duodenal ulcers associated with the use of non-steroidal anti-inflammatory drugs: a systematic review of preventive pharmacological interventions [Technology report no 38]. Ottawa: Canadian Coordinating Office for Health Technology Assessment; Available: (accessed 2006 Nov 28). 13. Ref ID: 3730 Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. 3rd. ed. Ottawa: The Agency; Available: (accessed 2007 Feb 9). 14. Ref ID: 3729 Barkun A, Sabbah S, Enns R, Armstrong D, Gregor J, Fedorak RN, et al. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 2004;99(7): Ref ID: 810 Briggs AH, Goeree R, Blackhouse G, O'Brien BJ. Probabilistic analysis of costeffectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002;22(4): Preventing NSAID induced GI complications: an economic evaluation of alternative strategies in Canada 23
24 16. Ref ID: 3090 Maetzel A, Ferraz MB, Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1998;41(1): Ref ID: 3774 Health costing in Alberta: 2006 annual report. Edmonton: Alberta Health and Wellness; 2006 Jul. Available: (accessed 2007 Feb 14). 18. Ref ID: 3085 Maetzel A, Krahn M, Naglie G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum 2003;49(3): Ref ID: 3772 Crott R, Makris N, Barkun A, Fallone C. The cost of an upper gastroduodenal endoscopy: an activity-based approach. Can J Gastroenterol 2002;16(7): Ref ID: 3780 Ministry of Health and Long Term Care. Schedule of benefits for physician services under the Health Insurance Act. Toronto: The Ministry; Available: _mn.html (accessed 2007 Feb 15). 21. Ref ID: 3278 Zakrzewska K, Valentine W, Roze S, Palmer A, Spinas G. Continuous subcutaneous insulin infusion reduces incidence of diabetes-related complications when compred with multiple daily injections for type 1 diabetes treatment: a health economic analysis in Switzerland. Diabetes 2005;54(Suppl 1):A Ref ID: 3731 Statistics Canada. Life tables, Canada, provinces and territories: Ottawa: Statistics Canada; Cat no 84=-537-XIE. Available: (accessed 2007 Feb 6). 23. Ref ID: 3771 Briggs AH, Gray AM. Handling uncertainty in economic evaluations of healthcare interventions. BMJ 1999;319(7210): Ref ID: 3777 Health care cost, quality, and outcomes: ISPOR book of terms. International Society for Pharmacoeconomics and Outcomes Research; Preventing NSAID induced GI complications: an economic evaluation of alternative strategies in Canada 24
Health Economics 101: PPI prescriptions in the Emergency Room
: PPI prescriptions in the Emergency Room Canadian Optimal Medication Prescribing & Utilization Service (COMPUS) Presented by: Chris Cameron October 26, 2007 What is Health Economics? Health economics
More informationSELECTED ABSTRACTS. Figure. Risk Stratification Matrix A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY
SELECTED ABSTRACTS A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY The authors of this article present a 4-quadrant matrix based on 2 key clinical parameters: risk for adverse gastrointestinal (GI)
More informationTECHNOLOGY OVERVIEW. Issue 6 February Economic Assessment: Celecoxib and Rofecoxib for Patients with Osteoarthritis or Rheumatoid Arthritis
TECHNOLOGY OVERVIEW Issue 6 February 2002 Economic Assessment: Celecoxib and Rofecoxib for Patients with Osteoarthritis or Rheumatoid Arthritis Publications can be requested from: CCOHTA 110-955 Green
More informationGastrointestinal Safety of Coxibs and Outcomes Studies: What s the Verdict?
Vol. 23 No. 4S April 2002 Journal of Pain and Symptom Management S5 Proceedings from the Symposium The Evolution of Anti-Inflammatory Treatments in Arthritis: Current and Future Perspectives Gastrointestinal
More informationDatabase of Abstracts of Reviews of Effects (DARE) Produced by the Centre for Reviews and Dissemination Copyright 2017 University of York.
A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling Brown
More informationCOMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées. Proton Pump Inhibitor Project Overview: Summaries
OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 1 March 2007 Proton Pump Inhibitor Project Overview: Summaries Supporting Informed Decisions À l appui des décisions éclairées This Executive Summary is based
More informationHave COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs?
et al. DOI:10.1111/j.1365-2125.2003.02012.x British Journal of Clinical Pharmacology Have COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs? Mary Teeling, Kathleen Bennett
More informationTechnology Report. Gastro-duodenal Ulcers Associated with the Use of Non-steroidal Antiinflammatory
Technology Report Issue 38 September 2003 Gastro-duodenal Ulcers Associated with the Use of Non-steroidal Antiinflammatory Drugs: A Systematic Review of Preventive Pharmacological Interventions Publications
More informationEffective management of gastrointestinal PROCEEDINGS EVALUATING THE APPROACHES TO SAFE AND EFFECTIVE ANALGESIA FOR OLDER PATIENTS WITH ARTHRITIS *
EVALUATING THE APPROACHES TO SAFE AND EFFECTIVE ANALGESIA FOR OLDER PATIENTS WITH ARTHRITIS * David A. Peura, MD, FACP, FACG ABSTRACT *This article is based on a presentation given by Dr Peura at the PRI-MED
More informationReview Article. NSAID Gastropathy: An Update on Prevention. Introduction. Risk Factors. Kam-Chuen Lai
Review Article NSAID Gastropathy: An Update on Prevention Kam-Chuen Lai Abstract: Keywords: Adverse reactions to non-steroidal anti-inflammatory drugs (NSAIDs) are common. Upper gastrointestinal complications
More informationSetting The setting was the community. The economic study was carried out in the USA.
Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis Yun H R, Bae S C Record
More informationCOMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées. Proton Pump Inhibitor Project Overview: Summaries
OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 1 March 2007 Proton Pump Inhibitor Project Overview: Summaries Supporting Informed Decisions À l appui des décisions éclairées This Executive Summary is based
More informationCOMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées
OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 6 March 2007 Gap Analysis Report for the Prescribing and Use of Proton Pump Inhibitors (PPIs) Supporting Informed Decisions À l appui des décisions éclairées
More informationScottish Medicines Consortium
Scottish Medicines Consortium ketoprofen/, 100mg/20mg; 200mg/20mg modified release capsules (Axorid ) No. (606/10) Meda Pharmaceuticals 05 February 2010 The Scottish Medicines Consortium (SMC) has completed
More informationNonsteroidal anti-inflammatory drugs (NSAIDs) are
GASTROENTEROLOGY 2003;125:389 395 Gastrointestinal Health Care Resource Utilization With Chronic Use of COX-2 Specific Inhibitors Versus Traditional NSAIDs LOREN LAINE,* JENIFER WOGEN, and HOLLY YU *University
More informationDecision makers have said that for pharmacoeconomic
Verification of a Decision Analytic Model Assumption Using Real-World Practice Data: Implications for the Cost Effectiveness of Cyclo-oxygenase 2 Inhibitors (COX-2s) Emily R. Cox, PhD; Brenda Motheral,
More informationA Cost-Effective Disease Management Approach to Minimizing NSAID-Related GI Mucosal Injury
A Cost-Effective Disease Management Approach to Minimizing NSAID-Related GI Mucosal Injury A. Mark Fendrick, MD Summary Nonsteroidal anti-inflammatory drugs (NSAIDs) are prescribed often in the U.S., particularly
More informationCOMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées
OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 5 March 2007 Current Practice Analysis Report for the Prescribing and Use of Proton Pump Inhibitors (PPIs) Supporting Informed Decisions À l appui des décisions
More informationMitigating GI Risks Associated with the Use of NSAIDs
bs_bs_banner Pain Medicine 2013; 14: S18 S22 Wiley Periodicals, Inc. Mitigating GI Risks Associated with the Use of NSAIDs Mahnaz Momeni, MD,* and James D. Katz, MD Departments of *Rheumatology, Medicine,
More informationSetting The setting was primary care. The economic study was carried out in Canada.
Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H-pylori-positive primary care patients with uninvestigated dyspepsia Chiba N, Van Zanten S J, Escobedo
More informationPreventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population?
Rheumatology Advance Access published December 20, 2005 Rheumatology 2005; 1 of 8 Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective
More informationCharacteristics of selective and non-selective NSAID use in Scotland
Characteristics of selective and non-selective NSAID use in Scotland Alford KMG 1, Simpson C 1, Williams D 2 1 Department of General Practice & Primary Care, The University of Aberdeen. 2 Department of
More informationModelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Tavakoli M
Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Tavakoli M Record Status This is a critical abstract of an economic
More informationSPECIAL REPORT. Aspirin and Risk of Gastroduodenal Complications
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:725 735 SPECIAL REPORT Proton Pump Inhibitors for Gastroduodenal Damage Related to Nonsteroidal Anti-inflammatory Drugs or Aspirin: Twelve Important Questions
More informationPapers. Abstract. Introduction. Methods. Jonathan J Deeks, Lesley A Smith, Matthew D Bradley
Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials Jonathan J Deeks, Lesley
More informationWhat is Bandolier? Balance benefits and harms
What is Bandolier? The first issue of Bandolier, an independent journal about evidence-based healthcare, written by Oxford scientists, (RAM AND HJM) was printed in February 1994. It has appeared monthly
More informationNon-steroidal anti-inflammatory drugs: who should receive prophylaxis?
Aliment Pharmacol Ther 2004; 20 (Suppl. 2): 59 64. Non-steroidal anti-inflammatory drugs: who should receive prophylaxis? C. J. HAWKEY Wolfson Digestive Diseases Centre, Institute of Clinical Research,
More informationHealth technology The study compared three strategies for diagnosing and treating obstructive sleep apnoea syndrome (OSAS).
Cost-effectiveness of split-night polysomnography and home studies in the evaluation of obstructive sleep apnea syndrome Deutsch P A, Simmons M S, Wallace J M Record Status This is a critical abstract
More informationAlgorithm for Use of Non-steroidal Anti-inflammatories (NSAIDs)
Algorithm for Use of Non-steroidal Anti-inflammatories (NSAIDs) Page 3 Publisher Conseil du médicament www.cdm.gouv.qc.ca Coordination Anne Fortin, Pharmacist Development Conseil du médicament Fédération
More informationPHARMACOTHERAPEUTIC ANALYSIS OF NON- STEROIDAL ANTI-INFLAMMATORY DRUGS PRESCRIBED AT RHEUMATOLOGY / ORTHOPEDIC CLINICS. Waleed M.
J. Al Azhar University-Gaza 2003,Vol. 6, 2 P.47-56 PHARMACOTHERAPEUTIC ANALYSIS OF NON- STEROIDAL ANTI-INFLAMMATORY DRUGS PRESCRIBED AT RHEUMATOLOGY / ORTHOPEDIC CLINICS. Waleed M. Sweileh An-Najah National
More information1. Comparative effectiveness of liraglutide
Cost-effectiveness of liraglutide (Victoza ) for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise. The NCPE has issued a recommendation regarding
More informationTECHNOLOGY OVERVIEW: PHARMACEUTICALS
TECHNOLOGY OVERVIEW: PHARMACEUTICALS ISSUE 3.1 JUNE 1996 PHARMACEUTICAL MANAGEMENT OF PEPTIC ULCER DISEASE prepared by Ms. Christine Perras, BSc Phm Pharmaceutical Associate, CCOHTA and Dr. Nicolaas Otten,
More informationNonsteroidal anti-inflammatory drugs (NSAIDs),
GASTROENTEROLOGY 2001;120:594 606 Approaches to Nonsteroidal Anti-inflammatory Drug Use in the High-Risk Patient LOREN LAINE University of Southern California School of Medicine, Los Angeles, California
More informationStudy population The study population comprised hypothetical patients with gastric and duodenal ulcer.
Evaluation of the cost-effectiveness of Helicobacter pylori eradication triple therapy vs. conventional therapy for ulcers in Japan Ikeda S, Tamamuro T, Hamashima C, Asaka M Record Status This is a critical
More informationNSAIDs: Side Effects and Guidelines
NSAIDs: Side Effects and James J Hale FY1 Department of Anaesthetics Introduction The non-steroidal anti-inflammatory drugs (NSAIDs) are a diverse group of drugs that have analgesic, antipyretic and anti-inflammatory
More informationORIGINAL ARTICLE. Abstract
ORIGINAL ARTICLE Prescription of Nonsteroidal Anti-inflammatory Drugs and Co-prescribed Drugs for Mucosal Protection: Analysis of the Present Status Based on Questionnaires Obtained from Orthopedists in
More informationThe management of arthritis and chronic pain syndromes
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:1337 1345 Impact of Adherence to Concomitant Gastroprotective Therapy on Nonsteroidal-Related Gastroduodenal Ulcer Complications JAY L. GOLDSTEIN,* KIMBERLY
More informationSetting The setting was primary care. The economic study was carried out in Brazil, France, Germany and Italy.
The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model Aballea S, Chancellor J, Martin M, Wutzler P, Carrat F, Gasparini R, Toniolo-Neto J, Drummond M, Weinstein
More informationSetting The setting was unclear. The economic study was conducted in Switzerland.
Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK Roze S, Valentine W J, Zakrzewska K E, Palmer A J Record
More informationPrevention of Acute NSAID-Induced Gastroduodenal Damage: Which Strategy is the Best?
Prevention of Acute NSAID-Induced Gastroduodenal Damage: Which Strategy is the Best? Shaden Salamae MD a, Meir Antopolsky MD a, Ruth Stalnikowicz MD a * Department of Emergency Medicine, Hadassah University
More informationSetting The setting was primary and secondary care. The economic study was carried out in Canada.
Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective Tarride J E, Gordon A, Vera-Llonch
More informationDeposited on: 8 May 2008 Glasgow eprints Service
Briggs, A.H. and Goeree, R. and Blackhouse, G. and O'Brien, B.J. (2002) Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Medical
More informationSetting The setting was secondary care. The economic study was carried out in Hong Kong, China.
Cost-effectiveness of Helicobacter pylori "test and treat" for patients with typical reflux symptoms in a population with a high prevalence of H. pylori infection: a Markov model analysis You J H, Wong
More informationDiscrepancy Among Observational Studies: Example of Naproxen- Associated Adverse Events
The Open Rheumatology Journal, 2009, 3, 1-8 1 Open Access Discrepancy Among Observational Studies: Example of Naproxen- Associated Adverse Events Elham Rahme *,1,2, Jean-Philippe Lafrance 3, Hacene Nedjar
More informationa newsletter detailing appropriate indications of IV PPI was sent to physicians;
Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions Kaplan G G, Bates D, McDonald D, Panaccione R, Romagnuolo J Record Status This is a critical abstract of an
More informationSource of effectiveness data The effectiveness data were derived from a review and synthesis of completed studies.
Economic evaluation of maintenance therapies for reflux esophagitis: comparison between step-up therapies and step-down therapies Sugano K, Kobayashi M Record Status This is a critical abstract of an economic
More informationMonth/Year of Review: January 2012 Date of Last Review: February 2007
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Month/Year of Review: January 2012 Date of Last Review:
More informationOsteoarthritis (OA) is the most prevalent joint
CURATA: A Patient Health Management Program for the Treatment of Osteoarthritis in Québec: An Integrated Approach to Improving the Appropriate Utilization of Anti-Inflammatory/Analgesic Medications Michèle
More informationHelicobacter pylori-associated ulcer bleeding: should we test for eradication after treatment Pohl H, Finlayson S R, Sonnenberg A, Robertson D J
Helicobacter pylori-associated ulcer bleeding: should we test for eradication after treatment Pohl H, Finlayson S R, Sonnenberg A, Robertson D J Record Status This is a critical abstract of an economic
More informationPharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori Taylor J L, Zagari M, Murphy K, Freston J W
Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori Taylor J L, Zagari M, Murphy K, Freston J W Record Status This is a critical abstract of an economic evaluation that
More informationDyspepsia tolerability from the patients perspective: a comparison of celecoxib with diclofenac
Aliment Pharmacol Ther 2002; 16: 819 827. Dyspepsia tolerability from the patients perspective: a comparison of celecoxib with diclofenac J. L. GOLDSTEIN*, G. M. EISEN, T. A. BURKEà, B. M. PEÑA, J. LEFKOWITH
More informationMeasuring Quality in Arthritis Care: The Arthritis Foundation s Quality Indicator Set for Analgesics
Arthritis & Rheumatism (Arthritis Care & Research) Vol. 51, No. 3, June 15, 2004, pp 337 349 DOI 10.1002/art.20422 2004, American College of Rheumatology ORIGINAL ARTICLE Measuring Quality in Arthritis
More informationPharmacoeconomic analysis of proton pump inhibitor therapy and interventions to control Helicobacter pylori infection Klok, Rogier Martijn
University of Groningen Pharmacoeconomic analysis of proton pump inhibitor therapy and interventions to control Helicobacter pylori infection Klok, Rogier Martijn IMPORTANT NOTE: You are advised to consult
More informationOutcomes assessed in the review The outcomes assessed in the review and used as model inputs were the incident rates of:
The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes Scuffham P, Carr L Record Status This is a critical abstract of
More informationHelicobacter pylori. Objectives. Upper Gastrointestinal Bleeding Peptic Ulcer Disease
Upper Gastrointestinal Bleeding Peptic Ulcer Disease Pharmacotherapy Issues in Acute Management and Secondary Prevention Peter J. Zed, B.Sc., B.Sc.(Pharm), Pharm.D. Pharmacotherapeutic Specialist - Emergency
More informationEvidence for Endoscopic Ulcers as Meaningful Surrogate Endpoint for Clinically Significant Upper Gastrointestinal Harm
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:1156 1163 REVIEW Evidence for Endoscopic Ulcers as Meaningful Surrogate Endpoint for Clinically Significant Upper Gastrointestinal Harm ANDREW MOORE,* INGVAR
More informationA Primer on Health Economics & Integrating Findings from Clinical Trials into Health Technology Assessments and Decision Making
Presenter: Chris Cameron CANNeCTIN November 8, 2013 A Primer on Health Economics & Integrating Findings from Clinical Trials into Health Technology Assessments and Decision Making Acknowledgements Vanier
More informationFaecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis Song K, Fendrick A M, Ladabaum U
Faecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis Song K, Fendrick A M, Ladabaum U Record Status This is a critical abstract of an economic evaluation
More informationManagement of nonsteroidal anti-inflammatory drug
BYRON CRYER, MD ABSTRACT OBJECTIVE: To describe risk factors and review appropriate management strategies for patients who experience nonsteroidal anti-inflammatory drug (NSAID)-related gastrointestinal
More informationEffective Health Care Program
Comparative Effectiveness Review Number 38 Effective Health Care Program Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review Executive Summary Background Osteoarthritis
More informationPRESCRIBING SUPPORT TEAM AUDIT: Etoricoxib hypertension safety evaluation
PRESCRIBING SUPPORT TEAM AUDIT: Etoricoxib hypertension safety evaluation DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY This audit has been designed to ensure that patients
More informationPrevalence of gastroduodenal lesions in chronic nonsteroidal anti-inflammatory drug users presenting with dyspepsia at the Kenyatta National Hospital
Research Article Department of Clinical Medicine and Therapeutics, University of Nairobi, Kenya Corresponding author: Dr. G O Oyoo. Email: geomondi@hotmail. com Prevalence of gastroduodenal lesions in
More informationStudy population The study population comprised a hypothetical cohort of patients with confirmed reflux oesophagitis.
Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK Wahlqvist P, Junghard O, Higgins A, Green J Record Status This is a critical
More informationA CASE STUDY OF VALUE OF INFORMATION
A CASE STUDY OF VALUE OF INFORMATION, Research Fellow 1/19 Background The ISPOR good practices for performance-based risk-sharing arrangements task force recommends using value of information analysis
More informationStressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU
Stressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds November 8, 2016 2016 MFMER slide-1 Objectives Identify the significance
More informationPATTERN OF USE OF GASTROPROTECTIVE AGENTS ALONG WITH THE ANTI INFLAMMATORY AND ANALGESICS DRUGS
PATTERN OF USE OF GASTROPROTECTIVE AGENTS ALONG WITH THE ANTI INFLAMMATORY AND ANALGESICS DRUGS K. B. Sanalkumar 1, K. T. Shenoy 2, K. Arun 3, Hema Ilavarasi K. M 4, Venugopalan P.G 5, Leena K. B 6 1Additional
More informationRecommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: Defining the role of gastroprotective agents
HOT TOPICS IN GASTROENTEROLOGY Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: Defining the role of gastroprotective agents Richard H Hunt MB FRCP FRCPC FACG
More informationORIGINAL ARTICLE. Abstract INTRODUCTION
International Journal of Rheumatic Diseases 2018 ORIGINAL ARTICLE Clinical and economic implications of upper gastrointestinal adverse events in Asian rheumatological patients on long-term non-steroidal
More information1. Comparative effectiveness of vedolizumab
Cost-effectiveness of vedolizumab (Entyvio ) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were
More informationSetting The setting was secondary care. The economic study was carried out in Canada.
Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis Rocchi A, Verma S Record Status This is a critical
More informationCARDIOVASCULAR RISK and NSAIDs
CARDIOVASCULAR RISK and NSAIDs Dr. Syed Ghulam Mogni Mowla Assistant Professor of Medicine Shaheed Suhrawardy Medical College, Dhaka INTRODUCTION NSAIDs are most commonly prescribed drugs Recent evidence
More informationResearch Study on the Prophylaxis of Gastrointestinal Side Effects of Non-Steroidal Anti-Inflammatory Drugs in Nova Scotia senior population
Research Study on the Prophylaxis of Gastrointestinal Side Effects of Non-Steroidal Anti-Inflammatory Drugs in Nova Scotia senior population by Bogdan Superceanu B00413930 bogdan@cs.dal.ca Performed for
More informationThis document has not been circulated to either the industry or Consultants within the Suffolk system.
New Medicine Report Document Status COX II Inhibitors In Acute Analgesia For Suffolk Drug & Therapeutics Committee Date of Last Revision 15 th February 2002 Reviewer s Comments There seems to be a growing
More informationA bleeding ulcer: What can the GP do? Gastrointestinal bleeding is a relatively common. How is UGI bleeding manifested? Who is at risk?
Focus on CME at the University of British Columbia A bleeding ulcer: What can the GP do? By Robert Enns, MD, FRCP Gastrointestinal bleeding is a relatively common disorder affecting thousands of Canadians
More informationNon-steroidal anti-inflammatory drugs and gastrointestinal damage problems and solutions
82 University of Glasgow and Department of Gastroenterology, Royal Infirmary, Glasgow Correspondence to: Professor R I Russell, 28 Ralston Road, Bearsden, Glasgow G61 3BA rirla@aol.com Submitted 26 October
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Duexis) Reference Number: CP.PMN.120 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationPDP 406 CLINICAL TOXICOLOGY
PDP 406 CLINICAL TOXICOLOGY Pharm.D Fourth Year NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) Mr.D.Raju.M.Pharm., Lecturer OPTIONS FOR LOCAL IMPLEMENTATION (1) NPC. KEY THERAPEUTIC TOPICS MEDICINES MANAGEMENT
More informationTOP 5 DRUGS.. TO AVOID IN THE ELDERLY
TOP 5 DRUGS.. TO AVOID IN THE ELDERLY Debbie Kwan, BScPhm., MSc., FCSHP Canadian Geriatrics Society, April 20, 2013 Disclosure of Potential for Conflict of Interest: Financial Disclosure: None Mar 26,
More informationBleeds in Cardiovascular Disease
Preventing Gastrointestinal Bleeds in Cardiovascular Disease Patients t on Aspirin i Joel C. Marrs, Pharm.D., BCPS Clinical Assistant Professor OSU/OHSU College of Pharmacy Pharmacy Practice IX (PHAR 766)
More informationAppendix. Lifetime extrapolation of data from the randomised controlled DiGEM trial
Appendix Lifetime extrapolation of data from the randomised controlled DiGEM trial Judit Simon, Alastair Gray, Philip Clarke, Alisha Wade, Andrew Neil, Andrew Farmer on behalf of the Diabetes Glycaemic
More informationPresentation Outline. Introduction to Biomedical Research Designs. EBM: A Practical Definition. Grade the Evidence (Example McMaster Grading System)
Presentation Outline Introduction to Biomedical Research Designs Sean D. Sullivan, R.Ph., PhD Professor of Pharmacy, Public Health and Medicine University of Washington Why a course in Biomedical Research
More informationThe New England Journal of Medicine
VERSUS AND IN REDUCING THE RISK OF RECURRENT ULCER BLEEDING IN PATIENTS WITH ARTHRITIS FRANCIS K.L. CHAN, M.D., LAWRENCE C.T. HUNG, M.D., BING Y. SUEN, R.N., JUSTIN C.Y. WU, M.D., KENNETH C. LEE, PH.D.,
More informationDeveloping Evidence-Based Best Practices for the Prescribing and Use of Proton Pump Inhibitors in Canada
Developing Evidence-Based Best Practices for the Prescribing and Use of Proton Pump Inhibitors in Canada Presented by: Sumeet R. Singh, COMPUS April 4, 2006 Background COMPUS Objective: To identify and
More informationA Cohort Study of NSAID Use and the Management of Related Gastrointestinal Symptoms by Primary Care Patients
A Cohort Study of NSAID Use and the Management of Related Gastrointestinal Symptoms by Primary Care Patients Christopher V. Chambers, MD, Walter L. Straus, MD, MPH, James J. Diamond, PhD, Lori A. Trapani,
More informationAlternative management strategies for patients with suspected peptic ulcer disease Fendrick M A, Chernew M E, Hirth R A, Bloom B S
Alternative management strategies for patients with suspected peptic ulcer disease Fendrick M A, Chernew M E, Hirth R A, Bloom B S Record Status This is a critical abstract of an economic evaluation that
More informationA study on clinical profile and risk factors in drug induced UGI bleeding
Original Research Article A study on clinical profile and risk factors in drug induced UGI bleeding S. Appandraj 1*, V. Sakthivadivel 2 1,2 Associate Professor, Dept. of General Medicine, Karpaga Vinayaga
More informationPharmacoeconomic Modeling of Prior-Authorization Intervention for COX-2 Specific Inhibitors in a 3-Tier Copay Plan
ORIGINAL RESEARCH Pharmacoeconomic Modeling of Prior-Authorization Intervention for COX-2 Specific Inhibitors in a 3-Tier Copay Plan JANE STACY, PharmD; ELIZABETH SHAW, MSIE; MICHELE D. ARLEDGE, PharmD;
More informationA cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis Choi H K, Seeger J D, Kuntz K M
A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis Choi H K, Seeger J D, Kuntz K M Record Status This is a critical abstract of an economic evaluation that meets
More informationPain therapeutics. Acetaminophen/NSAIDs Acute pain Osteoarthritis Migraine Acute Gout Neuropathic pain
Pain therapeutics Acetaminophen/NSAIDs Acute pain Osteoarthritis Migraine Acute Gout Neuropathic pain James McCormack, Pharm.D. Professor Faculty of Pharmaceutical Sciences, UBC Common types of pain killers
More informationA C A D E M I C D E TA I L I N G C H O O S I N G W I S E LY C O N F E R E N C E O C T 2 1, PA M M C L E A N - V E Y S E Y B S C P H A R M D R
PPI DEPRESCRIBING Canadian Deprescribing Network (CaDeN) goals are to: Reduce harm by raising awareness and cutting risky prescriptions for seniors by 50% by 2020. Promote health by ensuring access to
More informationHigh use of maintenance therapy after triple therapy regimes in Ireland
High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity
More informationNSAID-Induced Gastrointestinal Damage
GASTROENTEROLOGY BOARD REVIEW MANUAL STATEMENT OF EDITORIAL PURPOSE The Hospital Physician Gastroenterology Board Review Manual is a study guide for fellows and practicing physicians preparing for board
More informationThe first stop for professional medicines advice. Community Pharmacy NSAID Gastro-Intestinal Safety Audit
Community Pharmacy NSAID Gastro-Intestinal Safety Audit Working with Primary Care Commissioning, Strategy and Innovation Directorate The first stop for professional medicines advice www.sps.nhs.uk Community
More informationCost-effectiveness of hepatic venous pressure gradient measurements for prophylaxis of variceal re-bleeding Raines D L, Dupont A W, Arguedas M R
Cost-effectiveness of hepatic venous pressure gradient measurements for prophylaxis of variceal re-bleeding Raines D L, Dupont A W, Arguedas M R Record Status This is a critical abstract of an economic
More informationORIGINAL INVESTIGATION. Three-Tiered Copayment Drug Coverage and Use of Nonsteroidal Anti-inflammatory Drugs
ORIGINAL INVESTIGATION Three-Tiered Copayment Drug Coverage and Use of Nonsteroidal Anti-inflammatory Drugs Becky Briesacher, PhD; Sachin Kamal-Bahl, PhD; Marc Hochberg, MD, MPH; Denise Orwig, PhD; Kristijan
More informationCost-effectiveness ratios are commonly used to
... HEALTH ECONOMICS... Application of Cost-Effectiveness Analysis to Multiple Products: A Practical Guide Mohan V. Bala, PhD; and Gary A. Zarkin, PhD The appropriate interpretation of cost-effectiveness
More informationIs ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use?
ORIGINAL PAPER doi: 10.1111/j.1742-1241.2006.01147.x Is ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use? N. D. YEOMANS, 1 *L-ESVEDBERG,
More informationDATE: 07 December 2011 CONTEXT AND POLICY ISSUES
TITLE: versus Non-selective Non-steroidal Anti-Inflammatory Drugs and Proton Pump Inhibitors: Clinical Effectiveness, Safety, and Cost-Effectiveness DATE: 07 December 2011 CONTEXT AND POLICY ISSUES Non-steroidal
More information